Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C-Reference-Cited by-同舟云学术

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C

Published:2015-07-23 Issue:8 Volume:30 Page:1309-1316
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J Gastroenterol Hepatol

Author:

Ogawa Eiichi¹,Furusyo Norihiro¹,Kajiwara Eiji²,Nomura Hideyuki³,Kawano Akira⁴,Takahashi Kazuhiro⁵,Dohmen Kazufumi⁶,Satoh Takeaki⁷,Azuma Koichi⁸,Nakamuta Makoto⁹,Koyanagi Toshimasa¹⁰,Kotoh Kazuhiro¹¹,Shimoda Shinji¹²,Hayashi Jun¹³,

Affiliation:

1. Department of General Internal Medicine; Kyushu University Hospital; Fukuoka Japan

2. Department of Hepatology; Steel Memorial Yawata Hospital; Kitakyushu Japan

3. The Center for Liver Disease; Shin-Kokura Hospital; Kitakyushu Japan

4. Department of Medicine; Kitakyushu Municipal Medical Center; Kitakyushu Japan

5. Department of Medicine; Hamanomachi Hospital; Fukuoka Japan

6. Department of Internal Medicine; Chihaya Hospital; Fukuoka Japan

7. Center for Liver Disease; National Hospital Organization Kokura Medical Center; Kitakyushu Japan

8. Department of Medicine; Kyushu Central Hospital; Fukuoka Japan

9. Department of Gastroenterology, Kyushu Medical Center; National Hospital Organization; Fukuoka Japan

10. Department of Medicine; Fukuoka City Hospital; Fukuoka Japan

11. Department of Medicine and Bioregulatory Science; Kyushu University; Fukuoka Japan

12. Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

13. Kyushu General Internal Medicine Center; Haradoi Hospital; Fukuoka Japan

Funder

Janssen Pharmaceutical K.K.

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.12945/fullpdf

Reference27 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Impact of new hepatitis C treatments in different regions of the world;Wei;Gastroenterology,2014

3. Telaprevir for retreatment of HCV infection;Zeuzem;N. Engl. J. Med.,2011

4. Boceprevir for previously treated chronic HCV genotype 1 infection;Bacon;N. Engl. J. Med.,2011

5. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C;Furusyo;J. Hepatol.,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus;Gut and Liver;2017-07-15

2. Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment;Annals of Hepatology;2017-03

3. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis;Antiviral Research;2016-12

4. Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection;Hepatology Research;2016-10-26

5. Pharmacogenetics of ribavirin-induced anemia in HCV patients;Pharmacogenomics;2016-06